Plasminogen Activators (Plasminogen Activator)

A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation.

Also Known As:

Networked: 5435 relevant articles (95 outcomes, 561 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Vaughan, Douglas E: 27 articles (01/2015 - 05/2002)
2.	Rao, Jasti S: 25 articles (09/2013 - 02/2003)
3.	Høyer-Hansen, Gunilla: 21 articles (11/2015 - 05/2002)
4.	Brünner, Nils: 21 articles (11/2015 - 01/2002)
5.	Cines, Douglas B: 20 articles (04/2015 - 10/2002)
6.	Lawrence, Daniel A: 19 articles (06/2014 - 12/2002)
7.	Yang, Shun-Fa: 18 articles (01/2015 - 06/2003)
8.	Carmeliet, Peter: 18 articles (07/2014 - 03/2002)
9.	Eugen-Olsen, Jesper: 17 articles (10/2015 - 01/2007)
10.	Sobel, Burton E: 17 articles (10/2013 - 06/2003)

Related Diseases

1.	Hemorrhage 05/01/1996 - "These changes in the function of human arterial endothelial cells induced by plasminogen activators may affect regional vascular tone, endothelial permeability, and platelet aggregability, all of which are important in the efficacy of thrombolysis and in the pathogenesis of such vascular complications as rethrombosis and hemorrhage." 11/01/1995 - "Though plasminogen activators are effective in the treatment of thrombotic disorders, bleeding complications are associated with their use. " 01/01/1992 - "New developments in this field have centered around increasing the efficacy of the known plasminogen activators while employing methods to minimize the risk of hemorrhage and decrease the incidence of rethrombosis. " 05/01/2014 - "Complete plasminogen activator inhibitor type 1 (PAI-1) deficiency is an exceedingly rare autosomal recessive bleeding disorder previously identified and reported in a large Old Order Amish (OOA) kindred in Indiana [Fay et al. " 08/01/2013 - "Plasminogen activator inhibitor with very long half-life (VLHL PAI-1) can reduce bleeding in PAI-1-deficient patients."
2.	Thrombosis (Thrombus) 04/07/2005 - "Conservative management with plasminogen activator, could be considered as a good treatment for patients with acute porto-mesenteric thrombosis." 09/01/2015 - "This study therefore investigated the mutual relationship between thrombosis and HIF-1 activation in compressed mouse skin, based on a hypothesis that HIF-1 regulation by plasminogen activator inhibitor-1 (PAI-1) enhances thrombosis. " 04/01/2013 - "The objective of this study was to evaluate whether the presence of a plasminogen activator inhibitor type 1 (PAI-1) promoter polymorphism 4G/5G could significantly influence the proximal extension of vein thrombosis in spite of anticoagulant treatment in patients with calf vein thrombosis (CVT) following orthopaedic, urological and abdominal surgery. " 12/01/2002 - "In the present study, we analyzed the gene expression of plasminogen activator inhibitor-1 (PAI-1), a key molecule in the development of thrombosis, in a murine model of aging, klotho mutant ( kl/kl) mice. " 11/01/1995 - "The aim of this study was to measure the distribution of endogenous plasminogen activators during thrombolysis with an endothelial-conserving model of laminated thrombosis. "
3.	Myocardial Infarction 09/01/2010 - "Plasminogen activators provide effective treatment for patients with acute myocardial infarction. " 10/01/2005 - "Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction." 08/01/1999 - "Many studies have convincingly shown that survivors of myocardial infarction have impaired fibrinolytic activity because of increased concentrations of plasma plasminogen activator inhibitor-1 (PAI-1). " 07/01/1999 - "Several studies have found an association between high plasminogen activator inhibitor-1 (PAI-1) levels and myocardial infarction. " 10/01/1998 - "Several recent studies have reported contradicting results concerning the relevance of the plasminogen activator inhibitor-1 (PAI-1) 4G/5G-polymorphism for myocardial infarction. "
4.	Stroke (Strokes) 04/01/2013 - "Thrombolysis using intravenous recombinanttissue plasminogen activator (IV r-TPA) is the current gold standard for the treatment of acute ischaemic stroke (AIS). " 11/01/2014 - "Prolonged euglobulin clot lysis time (ECLT) and increased level of plasminogen activator inhibitor-1 (PAI-1) were reported to be risk factors of arterial ischemic stroke (AIS) by some studies; however, these findings were not supported by other studies. " 02/01/2011 - "The plasminogen activator inhibitor-1 gene polymorphism in determining the risk of pediatric ischemic stroke--case control and family-based study." 01/01/2010 - "Thrombolysis with intravenous tissue (IV) plasminogen activator (tPA) is considered for patients with acute ischemic stroke falling within the described inclusion criteria defined by The National Institute of Neurological Disorders and Stroke (NINDS) rtPA trial. " 07/01/2007 - "This study investigated the hypothesis that the insertion/deletion (4G/5G) polymorphism of the plasminogen activator inhibitor type-1 gene affects the risk for ischemic stroke, since results concerning this association have been controversial. "
5.	Neoplasms (Cancer) 02/01/1981 - "Fibrinolysis-inhibitory activity was estimated in the lysates of 21 lines of cultured human cancer cells, from which plasminogen activator activity had veen effectively eliminated by affinity chromatography. " 10/01/2010 - "Recent studies have demonstrated a poor prognosis for patients who have altered expression of plasminogen activator inhibitor type 1 (PAI-1) in several cancer types. " 09/01/1991 - "In our present study, we measured plasminogen activator inhibitor-1 (PAI-1) levels in plasmas from patients with various tumors. " 09/01/1989 - "[Study on the plasma plasminogen activators in patients with malignant gynecologic tumors]." 08/01/2015 - "Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing."

Related Drugs and Biologics

1.	Urokinase-Type Plasminogen Activator (Urokinase)
2.	Tissue Plasminogen Activator (Alteplase)
3.	Fibrinogen (Factor I)
4.	Plasminogen Activator Inhibitor 1
5.	Antigens
6.	Plasminogen
7.	Fibrin
8.	Fibrinolytic Agents (Antithrombotic Agents)
9.	Metformin (Glucophage)
10.	C-Reactive Protein

Related Therapies and Procedures

1.	Thrombolytic Therapy
2.	Catheters
3.	Stents
4.	Intra-Arterial Injections
5.	Compression Stockings